Lisata Therapeutics, Inc.
LSTA
$1.09
-$0.04-3.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -90.65% | -83.00% | -83.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.65% | -83.00% | -83.00% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -90.65% | -83.00% | -83.00% | -- | -- |
| SG&A Expenses | -0.66% | -8.67% | -13.62% | -5.82% | -1.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.12% | -22.87% | -21.49% | -9.95% | -8.47% |
| Operating Income | 21.78% | 20.10% | 18.75% | 14.51% | 12.91% |
| Income Before Tax | 24.53% | 17.42% | 15.57% | 10.84% | 9.07% |
| Income Tax Expenses | 59.77% | 59.77% | -20.55% | -20.55% | -20.55% |
| Earnings from Continuing Operations | 22.73% | 15.31% | 17.01% | 12.04% | 10.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.73% | 15.31% | 17.01% | 12.04% | 10.19% |
| EBIT | 21.78% | 20.10% | 18.75% | 14.51% | 12.91% |
| EBITDA | 21.45% | 19.95% | 18.77% | 14.58% | 12.95% |
| EPS Basic | 26.44% | 18.98% | 20.31% | 15.29% | 12.92% |
| Normalized Basic EPS | 28.30% | 21.13% | 18.55% | 13.77% | 11.51% |
| EPS Diluted | 26.44% | 18.98% | 20.31% | 15.29% | 12.92% |
| Normalized Diluted EPS | 28.30% | 21.13% | 18.55% | 13.77% | 11.51% |
| Average Basic Shares Outstanding | 5.09% | 4.53% | 4.29% | 3.86% | 3.16% |
| Average Diluted Shares Outstanding | 5.09% | 4.53% | 4.29% | 3.86% | 3.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |